Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953510 | 0.99 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53ALOX15MEN1KMT2A | |
| SCHEMBL6945832 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2TP53MEN1KMT2APDE1C | |
| SCHEMBL8099097 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53ALOX15MEN1KMT2A | |
| SCHEMBL8091021 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53MEN1KMT2APDE1C | |
| SCHEMBL8091377 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2TP53ALOX15MEN1KMT2A | |
| SCHEMBL6945817 | 0.84 | ALOX15 (0.51) | TP53ALOX15MEN1KMT2AALDH1A1 | |
| SCHEMBL6947901 | 0.82 | CYP2C9 (0.59) | TP53ALOX15MEN1KMT2AALDH1A1 | |
| SCHEMBL6953297 | 0.81 | MEN1 (0.54) | SMN1; SMN2TP53MEN1KMT2APDE1C | |
| SCHEMBL3032439 | 0.78 | MTOR (0.59) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 | |
| SCHEMBL8913648 | 0.78 | ADORA3 (0.52) | SMN1; SMN2TP53MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657431-B1 | 4-Phenyl-3-substituted 1,4-dihydropyridine esters with cerebral activity | BAYER AG (DE) | 2003-02-19 | — | — | EP | claimed |
| US-6066655-A | FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, IN PARTICULAR AS CEREBRAL THERAPEUTICS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-23 | — | — | US | disclosed |
| US-5731333-A | LEARNING AND MEMORY ENHANCEMENT, ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-03-24 | — | — | US | disclosed |